




# Extracorporeal Shockwave Therapy for Diabetic Foot Wounds and Ulcers: A Pilot RCT

1<sup>st</sup> May 2019


Hitchman, L.H. Smith, G.E. Chetter, I.C.


Academic Vascular Surgery Unit

Hull Royal Infirmary



# Background





## Extracorporeal Shockwave Therapy (ESWT)

- ✓ Low energy defocused shockwave
- ✓ Induce shearing forces
- ✓ Stimulate local inflammation
- ✓ Increase local cytokines and growth factors
- ✓ Possible bactericidal effect



# Current Evidence

## Snyder et al, 2018<sup>6</sup>

- Multi-centre RCT
- ESWT = 172 patients
- Control = 164 patients

% healed at 20 weeks:

**ESWT 35.5%**

**Control 24.4%**

**P=0.027**

## Jeppesen et al, 2016<sup>9</sup>

- Single centre RCT
- ESWT = 11 patients
- Control = 12 patients

% reduction at 7 weeks:

**ESWT 34.5%**

**Control 5.6%**

**p<0.01**

## Omar et al, 2014<sup>5</sup>

- Single centre RCT
- ESWT = 19 patients
- Control = 19 patients

% healed at week 20:

**ESWT 54%**

**Control 33.3%**

**P<0.05**

# Dosing Schedules

Study	Energy	Number of Shocks	Number of Treatments
<b>Jeppensen et al, 2016<sup>6</sup></b>	0.2mJ/mm <sup>2</sup> , 5Hz	500 + 250/cm <sup>2</sup>	6
<b>Omar et al, 2014<sup>5</sup></b>	0.11mJ/mm <sup>2</sup>	100/cm <sup>2</sup>	16
<b>Wang et al, 2011<sup>8</sup></b>	0.11mJ/mm <sup>2</sup>	≥500	6
<b>Moretti et al, 2009<sup>9</sup></b>	0.03mJ/mm <sup>2</sup>	100/cm <sup>2</sup>	3
<b>Wang et al, 2009<sup>10</sup></b>	0.11mJ/mm <sup>2</sup>	300 + 100/cm <sup>2</sup>	3
<b>Snyder et al, 2018<sup>7</sup></b>	0.23mj/mm <sup>2</sup>	500	6


## Systematic Review and Meta-analysis<sup>11</sup>:

- ✓ ESWT superior to standard care for wound healing [OR 2.66 95%CI 1.03-6.87]
  - ✓ ESWT superior to wound healing for time to healing [OR 2.45 95%CI 1.07-5.61]
  - Heterogeneous data
  - High risk of bias
- Need for further robust research


# Aims

1. To assess whether ESWT reduces the time to healing compared to standard wound care
2. To assess whether there is a dose-response to ESWT

# Methods



# Design - A single centre pilot RCT



# Population

## Inclusion Criteria:

- Open foot wound
- Diagnosis of Diabetes Mellitus
- ABPI > 0.8
- Over 18 years old
- Capacity to give consent

## Exclusion Criteria:

- Planned re-vascularisation procedure
- Anticoagulation
- Active malignancy in the treatment area
- Pregnancy or breast feeding
- Palliative

## Intervention 1

### ESWT

- 100 shocks/cm<sup>2</sup>
- 0.11mJ/mm<sup>2</sup>
- 5Hz
- Minimum 500 shocks
- Plus standard wound care<sup>11</sup>
- **3 sessions over 1 week**

## Intervention 2

### ESWT

- 100 shocks/cm<sup>2</sup>
- 0.11mJ/mm<sup>2</sup>
- 5Hz
- Minimum 500 shocks
- Plus standard wound care<sup>11</sup>
- **6 sessions over 2 weeks**

# Comparison

- Sham ESWT
- Plus Standard Wound Care<sup>11</sup>

## Outcomes

### ⌚ Primary Outcome - Time to wound healing

- Serial 2D photographs taken at wound reviews – blinded assessment

## Secondary Outcomes

- Clinical Outcomes:
  - Incidence of infection:
    - Clinical assessment and culture of wound swabs
  - Incidence of amputation
  - Changes in wound volume
    - 3D imaging
    - Assessed at 2, 4, 8, 12, 16 weeks
  - Recurrence Rate
  - Re-intervention Rate

## Secondary Outcomes

- Mechanism of Action:
  - Tissue perfusion
    - Doppler Flowmetry
  - Tissue integrity
    - Vapometer
  - Bacterial growth
    - Bacterial analysis

## ⌚ Secondary outcomes:

- Patient Outcomes:

- Quality of Life
- Pain

# Sample Size

● 40 per group

● 120 Total


# Progress

- Feasibility cohort study – recruiting

- PPI involvement in pilot design

## Summary

- 3 arm pilot exploratory RCT
- Open diabetic foot wounds
- Comparing
  - 3 treatments ESWT + standard care
  - 6 treatments ESWT + standard care
  - Sham ESWT + standard care
- To assess:
  - Time to healing
  - Dose response



## References

1. <https://www.diabetes.org.uk/professionals/position-statements-reports/statistics/diabetes-prevalence-2018>
2. Armstrong DG, Boulton AJM, Bus SA. Diabetic Foot Ulcers and Their Recurrence. *N Engl J Med.* 2017;376(24):2367-75.
3. Kerr M. Diabetic Foot Care In England: An Economic Study. *Diabetes UK;* 2017.
4. Smith GE, Long J, Wallace T, Carradice D, Chetter IC. On behalf of the Vascular Research Collaborative. Identifying research priorities in UK vascular surgery – a modified Delphi approach.2019. Submitted to *British Journal of Surgery*
5. Omar MT, Alghadir A, Al-Wahhab KK, Al-Askar AB. Efficacy of shock wave therapy on chronic diabetic foot ulcer: a single-blinded randomized controlled clinical trial. *Diabetes Res Clin Pract.* 2014;106(3):548-54.
6. Jeppesen SM, Yderstraede KB, Rasmussen BS, Hanna M, Lund L. Extracorporeal shockwave therapy in the treatment of chronic diabetic foot ulcers: a prospective randomised trial. *J Wound Care.* 2016;25(11):641-9.
7. Snyder R, Galiano R, Mayer P, Rogers LC, Alvarez O, Investigators ST. Diabetic foot ulcer treatment with focused shockwave therapy: two multicentre, prospective, controlled, double-blinded, randomised phase III clinical trials. *J Wound Care.* 2018;27(12):822-36.
8. Wang CJ, Wu RW, Yang YJ. Treatment of diabetic foot ulcers: a comparative study of extracorporeal shockwave therapy and hyperbaric oxygen therapy. *Diabetes Res Clin Pract.* 2011;92(2):187-93.
9. MorettiB, Notarnicola A, Maggio G, Moretti L, Pascone M, Tafuri S, et al. The management of neuropathic ulcers of the foot in diabetes by shock wave therapy. *BMC Musculoskelet Disord.* 2009;10:54.
10. Wang CJ, Kuo YR, Wu RW, Liu RT, Hsu CS, Wang FS, et al. Extracorporeal shockwave treatment for chronic diabetic foot ulcers. *J Surg Res.* 2009;152(1):96-103.
11. Hitchman LH, Totty JP, Raza A, Cai P, Smith GE, Carradice D, et al. Extracorporeal Shockwave Therapy for Diabetic Foot Ulcers: A Systematic Review and Meta-Analysis. *Ann Vasc Surg.* 2018.



# Questions

